AUTHORS
Shaowei Qiu, MD, Shaoyuan Wang2, Li Wang3, Qingliang Teng4, Fei Li5, Meiyun Fang6, Jinhai Ren, MD7, Yuguang Wang, PhD8, Jing Wang9, Qianqian Liang10, Yuanyuan Pan11, Jincai Bai12, Hui Wei, MD, PhD13, Jianxiang Wang Sr, MD, PhD14
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China
3 Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
4 Taian Central Hospital, Taian, China
5 Jiangxi Provincial Key Laboratory of Hematological Diseases, Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
6 Hospitals With Foreign Department in Dalian, Dalian, China
7 The second hospital of Hebei medical university, Shijiazhuang, China
8 MaxiNovel Pharmaceuticals Co.,Ltd., Beijing, China
9 MaxiNovel Pharmaceuticals Co.,Ltd., Beijing, China
10 MaxiNovel Pharmaceuticals Co.,Ltd., Beijing, China
11 MaxiNovel Pharmaceuticals Co.,Ltd., Beijing, China
12 MaxiNovel Pharmaceuticals Co.,Ltd., Beijing, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Background: Newly diagnosed acute myeloid leukemia (AML) patients unfit for intensive chemotherapy (IC) due to significant comorbidities or advanced age (≥ 75 years) have limited treatment options and poor prognosis. Although venetoclax (VEN) combined with azacitidine (AZA) is recommend as standard-of-care, treatment outcomes remain suboptimal, especially in high risk subtype including FLT3-ITD, TP53, RAS pathway mutations. Thus, it is important to explore whether the addition of novel agents to the VEN+AZA regimen would improve the clinical efficacy. MAX-40279 is a novel multi- kinase (MTK) inhibitor targeting FLT3, FGFR, JAK, ROS and LYN. This ongoing study evaluates addition of MAX-40279 to the VEN+AZA backbone for unfit newly diagnosed AML. Herein, we report the interim dose escalation results of this trial.
Method: This is a prospective, multicenter, phase ? study consisting of dose escalation and expansion stages in unfit newly diagnosed AML. The present analysis represents an interim analysis of the completed dose escalation stage; dose expansion cohorts are actively enrolling. Patients in dose escalation stage received oral MAX-40279 at 40 mg, 50 mg, and 60 mg twice daily (BID), in combination with VEN and AZA in 28-day cycles. Three to six patients were enrolled at each dose level. The dose-limiting toxicities (DLTs) observation period was 28?days after the first dose. All evaluable patients with ≥1 cycle treatment were included in preliminary efficacy analysis. The primary endpoints were safety and tolerability to define the recommended phase 2 dose (RP2D), and composite complete remission (CRc) rate was also assessed.
Result: Sixteen unfit AML patients were enrolled and treated across three dose cohorts (40 mg BID, n=6; 50 mg BID, n=7; 60 mg BID, n=3). Baseline characteristics reflected a high-risk population: median age of 68.5 years (range, 54-85), bone marrow blasts ≥50% (43.8%, 7/16), transfusion dependence (43.8%, 7/16) and adverse-risk stratification (50%, 8/16). No DLTs were observed at any dose level. No treatment-related permanent treatment discontinuation or death occurred. The most common grade ≥3 treatment-related adverse events (TRAEs, incidence ≥20%) included leukopenia (81.3%, 13/16), neutropenia (75.0%, 12/16), thrombocytopenia (43.8%,7/16), and infection (25.0%, 4/16). Among 15 efficacy-evaluable patients, CRc rates varied across dose cohorts: 33.3% (2/6) at 40 mg BID, 100% (6/6) at 50 mg BID cohort and 33.3% (1/3) at 60 mg BID. Notably, 100% (2/2) CR in FLT3-ITD and 75% (3/4) response rates (including morphologic leukemia-free state [MLFS] and CR) in TP53 or RAS pathway mutations. In the 50 mg BID cohort, all patients achieved transfusion independence and no FLT3-muted AML patients enrolled. Based on the overall results, 50 mg BID was selected as the preliminary RP2D for subsequent expansion.
Conclusion: These interim results demonstrate that triplet therapy combining MAX-40279 with VEN+AZA is well tolerated and notable efficacy in unfit newly diagnosed AML patients, including those with high-risk molecular features. These encouraging early findings support continued dose expansion enrollment. Mature safety and efficacy data from the ongoing expansion cohort will further define the clinical value of this novel triplet regimen for improving outcomes in unfit AML, high-risk patients.
DISCLOSURES
Shaowei Qiu, MD: No relevant conflicts of interest to declare.